Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RBBP8 antisense RNA 1 (RBBP8-AS1, also known as AC090912.1) is a long non-coding RNA (lncRNA) classified specifically as a natural antisense transcript (NAT). It is transcribed from the DNA strand opposite to the protein-coding gene RBBP8. As with other antisense RNAs, it is believed to play a role in the regulation of its sense (RBBP8) gene’s expression, chiefly through mechanisms such as transcriptional interference and chromatin remodeling. These lncNATs may impact gene expression at the levels of transcription and translation by mechanisms including promoter competition, occlusion, or dislodgement of RNA polymerase, although detailed functional characterization specific to RBBP8-AS1 has not been published. RBBP8-AS1 is not recognized as a traditional therapeutic target such as a receptor, enzyme, transporter, or protein; instead, its classification as a regulatory RNA places it primarily in the field of gene expression modulation research rather than classical drug targeting[3][5][6][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RBBP8 antisense RNA 1 (RBBP8-AS1).